STOCK TITAN

Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 5:20 p.m. ET. A live webcast will be available on the company's website, with a replay for 30 days post-event. Sutro, based in South San Francisco, specializes in drug discovery and manufacturing, focusing on cancer and autoimmune therapeutics through its innovative protein engineering platforms. Key product candidates include STRO-001 and STRO-002, both undergoing Phase 1 trials for various cancers.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Bill Newell, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, Jan. 14, 2021 at 5:20 p.m. ET / 2:20 p.m. PT.

A live webcast of the presentation will be accessible through the News & Events page of the Investor Relations section of the company's website at www.sutrobio.com. A replay of the webcast will be available for approximately 30 days following the event.

About Sutro Biopharma
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Sutro's proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro's first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma. STRO-001 was granted Orphan Drug Designation by the FDA for multiple myeloma in October 2018. STRO-002 is a folate receptor alpha (FolRα)-targeting ADC, currently being investigated in a Phase 1 clinical trial of patients with ovarian and endometrial cancers. This is the second product candidate to be evaluated in clinical trials resulting from Sutro's XpressCF® and XpressCF+™ technology platforms. A third program, CC-99712 (BCMA-targeting ADC), which is part of Sutro's collaboration with Bristol Myers Squibb (formerly Celgene Corporation), is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma. Sutro's proprietary technology was responsible for the discovery and manufacturing of CC-99712, for which Bristol Myers Squibb has worldwide development and commercialization rights. Sutro is entitled to development and regulatory milestone payments and tiered royalties from Bristol Myers Squibb for this BCMA ADC. Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.

To date, Sutro's platform has led to cytokine-based immuno-oncology therapies, ADCs, vaccines and bispecific antibodies directed at precedented targets in clinical indications where the current standard of care is suboptimal.

The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.

In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements the Company makes regarding its expected use of proceeds and anticipated preclinical and clinical development activities, timing of clinical trials and announcements of clinical results, potential benefits of the Company's product candidates and platform and potential market opportunities for the Company's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company's expected use of proceeds and the Company's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the impact of the COVID-19 pandemic on the Company's business, clinical trial sites, supply chain and manufacturing facilities, the Company's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company's ability to fund development activities and achieve development goals, the Company's ability to protect intellectual property, and the Company's commercial collaborations with third parties and other risks and uncertainties described under the heading "Risk Factors" in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contacts
Annie J. Chang
Sutro Biopharma
(650) 801-5728
ajchang@sutrobio.com

Media Contacts
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com 

Cision View original content:http://www.prnewswire.com/news-releases/sutro-biopharma-to-present-at-the-39th-annual-jp-morgan-virtual-healthcare-conference-301200782.html

SOURCE Sutro Biopharma

FAQ

When is Sutro Biopharma's presentation at the J.P. Morgan Healthcare Conference?

Sutro Biopharma's presentation will take place on January 14, 2021, at 5:20 p.m. ET.

How can I access the webcast of Sutro Biopharma's conference presentation?

The live webcast can be accessed through the News & Events page on Sutro Biopharma's investor relations website.

What is the focus of Sutro Biopharma's drug development?

Sutro Biopharma focuses on creating next-generation cancer and autoimmune therapeutics using precise protein engineering.

What are STRO-001 and STRO-002?

STRO-001 and STRO-002 are Sutro Biopharma's first two antibody-drug conjugates currently in Phase 1 clinical trials for various cancers.

What was granted Orphan Drug Designation by the FDA?

STRO-001 received Orphan Drug Designation from the FDA for multiple myeloma in October 2018.

Sutro Biopharma, Inc.

NASDAQ:STRO

STRO Rankings

STRO Latest News

STRO Stock Data

302.45M
81.96M
0.96%
78.2%
3.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO